Johan H. Neyts

This study evaluates antiviral sugar baits (AVSBs) in mosquitoes to block dengue and chikungunya virus transmission, finding that 4'FlU and JNJ-A07 reduce viral infection and dissemination.

This study evaluates cross-protection of Ebola and Sudan vaccines against Bundibugyo virus using a surrogate challenge model in mice, finding partial protection and suggesting non-neutralizing mechanisms play a role.

This study characterizes the multiphasic viral replication kinetics of rat HEV in vivo, showing liver as the main replication site and ribavirin's partial efficacy in preventing viral rebound.

This study develops a yellow fever 17D reporter virus expressing thymidine kinase to enable prodrug activation and bioorthogonal labeling of infected cells for tracking viral replication and tissue tropism.

This paper introduces human myelin spheres (MyS) as a model for studying myelination and demyelination, showing their ability to form myelinated neurons and mimic in vivo oligodendrocyte development.

This paper develops a high-throughput imaging platform for RV-C research and antiviral drug discovery, identifying inhibitors through compound screening.

This study shows that Oropouche virus causes severe congenital malformations and neurodevelopmental issues in embryonic mice, mirroring human fetal cases.

This study shows 4'-fluorouridine inhibits Oropouche virus replication in vitro and in animal models, with no resistant variants observed.

This study establishes an HEV-HIE model showing HEV replication in intestinal epithelial cells, with proliferative cells being the main targets, suggesting the gut as an HEV reservoir.

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

The paper identifies orally bioavailable inhibitors of the Zika virus NS2B-NS3 protease that show antiviral activity in vitro and reduce viral RNA load in a murine infection model.

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

This study evaluates combinations of approved oral nucleoside analogues against multiple alphaviruses in vitro and in vivo, finding synergistic antiviral effects and reduced viral mutation rates with combination therapy.

This study demonstrates that enterovirus 2A protease is critical for viral replication and evasion of host antiviral responses through multiple mechanisms.

This study shows that combining remdesivir and ribavirin significantly reduces HPIV-3 infection in cell cultures and mice, with minimal lung pathology.

This study shows that antigenic imprinting limits neutralizing antibody responses to new SARS-CoV-2 variants in hamsters, suggesting challenges for vaccine efficacy against emerging subvariants.

This paper evaluates a triple antiviral combination's efficacy against coronavirus in cell cultures and a hamster model, finding enhanced antiviral effects even with suboptimal doses.

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

The paper identifies 62 new inhibitors of SARS-CoV-2 3CL-Pro through a compound repurposing screen and validates their activity using X-ray crystallography.

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.